| Medical marijuana and the developing role of the pharmacist. | |
| | |
MedLine Citation:
|
PMID: 17494903 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: The pharmacology, therapeutic uses, safety, drug-drug interactions, and drug-disease interactions of medical marijuana are reviewed, and the legal issues related to its use and the implications of medical marijuana for the pharmacist are presented. SUMMARY: Marijuana contains more than 460 active chemicals and over 60 unique cannabinoids. The legal landscape surrounding marijuana is surprisingly complex and unsettled. In the United States, 11 states and several municipalities have legalized medical marijuana. Another state provides legislation that allows patients to claim a defense of medical necessity. Nevertheless, patients using medical marijuana may never interact with a pharmacist. Marijuana is a Schedule I controlled substance and its use is illegal under federal law. Marijuana has a number of purported therapeutic uses with a broad range of supporting evidence. There are five general indications for medical marijuana: (1) severe nausea and vomiting associated with cancer chemotherapy or other causes, (2) weight loss associated with debilitating illnesses, including HIV infection and cancer, (3) spasticity secondary to neurologic diseases, such as multiple sclerosis, (4) pain syndromes, and (5) other uses, such as for glaucoma. Marijuana is associated with adverse psychiatric, cardiovascular, respiratory, and immunologic events. Moreover, marijuana may interact with a number of prescription drugs and concomitant disease states. CONCLUSION: Several states have legalized the use of marijuana for chronic and debilitating medication conditions. Pharmacists need to understand the complex legal framework surrounding this issue so that they can protect themselves and better serve their patients. |
| | |
Authors:
|
Matthew J Seamon; Jennifer A Fass; Maria Maniscalco-Feichtl; Nada A Abu-Shraie |
Related Documents
:
|
3687953 - Asbestos disease in sheet metal workers: ii. radiologic signs of asbestosis among activ... 17693313 - Determination of delta9-tetrahydrocannabinol in indoor air as an indicator of marijuana... 19396023 - For debate: childhood obesity - is there hope for therapy and prevention? |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Volume: 64 ISSN: 1079-2082 ISO Abbreviation: Am J Health Syst Pharm Publication Date: 2007 May |
Date Detail:
|
Created Date: 2007-05-14 Completed Date: 2007-07-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9503023 Medline TA: Am J Health Syst Pharm Country: United States |
Other Details:
|
Languages: eng Pagination: 1037-44 Citation Subset: IM |
Affiliation:
|
College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA. mseamon@nova.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cannabis* Drug Interactions Drug and Narcotic Control Humans Pharmacists / legislation & jurisprudence* Phytotherapy Tetrahydrocannabinol / adverse effects, pharmacology, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
1972-08-3/Tetrahydrocannabinol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hyperglycemia management in the hospital setting.
Next Document: Quetiapine for acute mania in bipolar disorder.